Subgroup analysis of the total population according to the diabetes status showed that SGLT2 inhibitors significantly reduced the risk of HHF both in patients with and without diabetes (HR = 0.68, 95% CI: 0.60–0.76; I2 0% and HR = 0.69, 95% CI: 0.56–0.84; I2 0%, respectively) (Figure 5), as well as the risk of HHF or CV death (HR = 0.70, 95% CI: 0.64–0.77; I2 0% and HR = 0.75, 95% CI: 0.66–0.87; I2 0%, respectively) (Figure 6). The gene discussed is SLC5A2; the disease is diabetes mellitus.